

CHOATE, HALL & STEWART

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS

EXCHANGE PLACE

53 STATE STREET

BOSTON, MASSACHUSETTS 02109-2804

TELEPHONE (617) 248-5000 • FAX (617) 248-4000

WWW.CHOATE.COM

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

TELECOPY TRANSMITTAL SHEET**CONFIDENTIAL****RECEIVED**

APR 01 2002

Technology Center 2100

Number of pages being sent 7 (including this page)**DATE:**

February 11, 2002

Recipient	Company	Fax No.	Phone No.
1. Assistant Commissioner of Patents		703-308-4556	703-308-1234

FROM: Amy F. Lewis, Ph.D., Staff Scientist**DIRECT DIAL:** 617-248-2118

REMARKS: RE: Applicant: Fount, *et al.*
Serial No.: 09/728,720
Filed: December 1, 2000
For: PREVENTION AND TREATMENT OF HCV INFECTION
EMPLOYING ANTIBODIES DIRECTED AGAINST
CONFORMATIONAL EPITOPES.

Please find for filing in the above-referenced case, documents listed on the attached Transmittal. Kindly file immediately.

TIME SENT: _____ **OPERATOR:** _____ **CLIENT NO.** 2002850-0009

Return by: Inter-office Mail _____ Hold for pick-up _____

THIS TRANSMITTAL IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS TRANSMITTAL IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE TRANSMITTAL TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY.

**ATTORNEY DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED

Applicant: Fount, *et al.*

Examiner: APR 24 2002

Serial No.: 09/728,720

Art Unit: 2TECH CENTER 1600/2900

Filed: December 1, 2000

For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

TRANSMITTAL

CERTIFICATE OF FACSIMILE TRANSMISSION
PURSUANT TO 1096 OG 30-31
I hereby certify that this paper is being
facsimile transmitted to the Assistant
Commissioner For Patents, Washington,
DC 20231,
on February 11, 2002
Kathleen Hart

Enclosed please find the following documents regarding the above-referenced matter:

1. Preliminary Amendment (3 pages);
2. Version with Markings Showing Changes made (2 pages); and
3. Return postcard.

RECEIVED

APR 01 2002

Technology Center 2100

If there are any charges or credits associated with this matter, please apply them to Deposit
Account No. 03-1721.

Respectfully submitted,

Dated: February 11, 2002

Karoline K. M. Shair
Karoline K. M. Shair, Ph.D.
Reg. No.: 44,332 *for*
Brenda Hershbach Jarrell, Ph.D.
Reg. No.: 39,223

CHOATE HALL & STEWART
Exchange Place
53 State Street
Boston, MA 02109
Telephone: (617) 248-5000
Facsimile: (617) 248-4000

U.S.S.N. 09/728,720
3364342_1.DOC

Page 1 of 1

Atty. Docket No.: 2002850-0009
Stanford Docket No.: S98-161 US CIP II

05/03/2002 09:52 00000001 031721 09728720

01 FC:203 288.00 CH
02 FC:202 84.00 CH

02/11/02 MON 15:19 [TX/RX NO 5975] 002

ATTORNEY DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 24 2002

Applicant: Foung, et al.

Examiner:

Serial No.: 09/728,720

Art Unit: 2152

TECH CENTER 1600/2900

Filed: December 1, 2000

For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPESAssistant Commissioner For Patents
Washington, DC 20231CERTIFICATE OF FACSIMILE TRANSMISSION
PURSUANT TO 1096 OG 30-31
I hereby certify that this paper is being
facsimile transmitted to the Assistant
Commissioner For Patents, Washington,
DC 20231

Sir:

PRELIMINARY AMENDMENT

ON

February 11, 2002
Rachy West Progen

Applicants submit the following Preliminary Amendment and Remarks.

AMENDMENT

RECEIVED

APR 01 2002

Technology Center 2100

In the Claims:

Please add the following new claims.

75
72. A combination of two or more antibodies directed to one or more conformational epitopes of E2 protein of Hepatitis C virus.

76
73. The combination of two or more antibodies of claim 72, wherein the combination results in increased binding of the antibodies to one or more conformational epitopes of E2 protein of Hepatitis C virus.

77
74. The combination of two or more antibodies of claim 73, wherein the increased binding of two or more antibodies to the one or more conformational epitopes of E2 protein of Hepatitis C virus is greater than 100% relative to the binding of a single antibody.

78
75. The combination of two or more antibodies of claim 72 comprising CBH-7 and CBH-4G.